Log in
NASDAQ:AMYT

Amryt Pharma Stock Forecast, Price & News

$12.60
0.00 (0.00 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.60
Now: $12.60
$12.60
50-Day Range
$10.83
MA: $12.18
$13.50
52-Week Range
$10.06
Now: $12.60
$15.50
Volume12 shs
Average Volume28,044 shs
Market Capitalization$432.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Amryt Pharma Holdings Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMYT
CUSIPN/A
CIKN/A
Phone353-1518-0200
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$58.12 million

Profitability

Miscellaneous

Market Cap$432.67 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$12.60
0.00 (0.00 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amryt Pharma (NASDAQ:AMYT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Amryt Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amryt Pharma
.

When is Amryt Pharma's next earnings date?

Amryt Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Amryt Pharma
.

How were Amryt Pharma's earnings last quarter?

Amryt Pharma Holdings Ltd (NASDAQ:AMYT) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.12) EPS for the quarter. The company earned $46.19 million during the quarter.
View Amryt Pharma's earnings history
.

What price target have analysts set for AMYT?

2 brokers have issued twelve-month target prices for Amryt Pharma's stock. Their forecasts range from $40.00 to $45.00. On average, they expect Amryt Pharma's share price to reach $42.50 in the next twelve months. This suggests a possible upside of 237.3% from the stock's current price.
View analysts' price targets for Amryt Pharma
.

Who are some of Amryt Pharma's key competitors?

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT."

How do I buy shares of Amryt Pharma?

Shares of AMYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately $12.60.

How big of a company is Amryt Pharma?

Amryt Pharma has a market capitalization of $432.67 million and generates $58.12 million in revenue each year.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The company can be reached via phone at 353-1518-0200 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.